Comparative pharmacokinetics of the three echinocandins in ICU patients

10Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We conducted a prospective study in ICU patients of two tertiary hospitals in order to determine basic pharmacokinetic (PK) parameters, associated variation and target attainment rates for anidulafungin, micafungin and caspofungin. Methods: Serum samples from patients treated for 7 days with the standard doses of anidulafungin (N= 13), micafungin (N= 14) or caspofungin (N= 7) were analysed by validated chromatographic methods. PK parameters determined with non-compartmental analysis were correlated with demographic, laboratory and disease severity characteristics. The percentages of patients attaining drug exposures described in the summary of product characteristics (SmPC) documents and preclinical PK/PD targets for stasis were estimated. Results: The median (range) AUC24 was 101.46 (54.95-274.15)mg-h/L for anidulafungin, 79.35 (28.00- 149.30)mg-h/L for micafungin and 48.46 (19.44-103.69)mg-h/L for caspofungin. The interindividual variability of anidulafungin, micafungin and caspofungin AUC24 was 46%-58%, attributed mainly to variability in volume of distribution (V), clearance (CL) and in both V and CL, respectively. Significant correlations were found between anidulafungin AUC24 and BMI (rs =#0.670, P = 0.012) and liver enzymes (rs = 0.572-0.665, P = 0.013-0.041) and between caspofungin Cmin and transaminase levels (rs =#0.775 to #0.786, P = 0.036-0.041). Less than 50% of our patients attained the corresponding SmPC median AUC24s and none of the patients attained the PK/PD targets for Candida albicans and Candida parapsilosis. Conclusions: Anidulafungin exposure in ICU patients was comparable with that reported in non-ICU patients and in healthy volunteers. Micafungin exposure was comparable to that of other patients but-30% lower than that in healthy volunteers, whereas caspofungin exposure was rather low (-50% lower than in healthy volunteers). Larger interindividual variability (50%-60%) was recorded in ICU patients compared with other groups for all three echinocandins.

Cite

CITATION STYLE

APA

Mainas, E., Apostolopoulou, O., Siopi, M., Apostolidi, S., Neroutsos, E., Mirfendereski, H., … Meletiadis, J. (2020). Comparative pharmacokinetics of the three echinocandins in ICU patients. Journal of Antimicrobial Chemotherapy, 75(10), 2969–2976. https://doi.org/10.1093/jac/dkaa265

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free